Document is current

Article History

Received: 9 February 2022

Accepted: 19 April 2022

First Online: 7 May 2022

Declarations

:

: The study is fully compliant with the Health Insurance Portability and Accountability Act. The protocol was reviewed and deemed exempt from Institutional Review Board (IRB) oversight using the Department of Health and Human Services regulations found at 45 CFR 46.104 (d)(4) (Advarra IRB; Pro00056338; August 4, 2021).

: A waiver of informed consent was received from Advarra IRB.

: Not Applicable.

: FC has received institutional grants and research support from Amgen; has served as a consultant for Amgen, Radius Health, Inc. (Radius), Enterabio, Haoma, Obseva, and Myovant; has served on the speakers’ bureaus for Amgen and Radius; and has served on advisory boards for Amgen and Radius. She is also co-editor in chief of <i>Osteoporosis International</i>. CC has received lecture fees and honoraria from Amgen, Danone, Eli Lilly, GSK, Medtronic, Merck, Nestlé, Novartis, Pfizer, Roche, Servier, Shire, Takeda, and UCB; YW, BM, SV, and SAW are employees and shareholders of Radius. CC is also the president of International Osteoporosis Foundation, a sponsor of <i>Osteoporosis International</i>.

: The authors declare that they have no personal conflicts.